Loading
Masonite International buys Lemieux Doors
Tampa's Masonite International Corp. has completed the acquisition of all of the capital stock of Windsor, Quebec-based Lemieux Doors Inc. Founded in 1990, Lemieux is known for panel and French wood doors. Lemieux employs 150 people and has annual revenue of more than $40 million.
“Lemieux's products and capabilities complement Masonite's existing residential wood door offerings and provide an important additional platform of strategic growth for our company,” Chris Virostek, Masonite's senior vice president of corporate development, says in a press release.
Masonite International is a global manufacturer of residential and commercial doors.
Alico board of directors approves quarterly dividend
The board of directors of Fort Myers-based Alico Inc. declared a fourth quarter cash dividend of 4 cents per share on its outstanding common stock. The dividend is to be paid to shareholders of record as of Sept. 29 with the payment expected Oct. 15.
Alico saw its revenue increase from $36.49 million in the first three months of 2011 to $54.13 million in the same quarter this year. At the same time, net income more than doubled during the same period to $7.41 million. The dividend also comes as Alico announced an agreement to sell 5,187 acres in Lee County to Private Equity Group LLC for $10 million.
Alico owns and manages 130,300 acres in Collier, Glades, Hendry, Lee and Polk counties.
TECO Energy declares quarterly dividend
TECO Energy directors have declared a dividend of 22 cents per share of common stock. The dividend is payable to shareholders of record as of Aug. 14.
Jabil issuing $500 million in new debit at 4.7%
Jabil Circuit Inc. plans to offer $500 million of senior unsecured notes. The debt will be due in 2022 and is priced at 4.7%.
Jabil expects to use the net proceeds to repay outstanding borrowings under its revolving senior credit facility and for general corporate purposes.
RBS Securities Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated will act as joint book-running managers for the offering.
Jabil provides electronics design, manufacturing and product management services to global electronics and technology companies.
Vista System providing signage to European fast food chain
Sarasota-based Vista System International sold its menu boards to European sign company Austroflex Lichtreklame Erzeugung for installation at one of the branches of U Box in Vienna, a leading fast food chain in Austria. More of Vista System's menu boards and signs will be installed at other branches of the chain in the future.
Nine menu boards were installed in the branch. Austroflex Lichtreklame Erzeugung was commissioned not only as sign suppliers, but also took part in the design of the entire electric and lighting systems, together with the owner and designer of the whole project.
As Seen On TV Inc. hires digital marketer for website
Clearwater-based As Seen On TV Inc. has signed a marketing agreement with BrightShop Digital, a division of New York City's Primary Wave Music, to market the relaunch of AsSeenOnTV.com.
The company has also created social media extensions for the website on Facebook (facebook.com/OfficialAsSeenOnTV), Pinterest and Youtube.
Over the next few months, promotions involving product and company Web videos, contests, digital coupons and various fan engagement activities will be rolled out.
BrightShop is a boutique digital marketing and production agency focused on developing and executing fully customized digital marketing.
Wellness Center USA buys Tampa's CNS-Wellness LLC
Wellness Center USA Inc., a Schaumburg, Ill.-based health care and nutritional supplement company, completed its purchase of Tampa's CNS-Wellness LLC.
CNS Wellness LLC is a cognitive neuroscience company specializing in the treatment of brain-based behavioral health disorders without drugs.
Wellness Center USA and CNS Wellness expect to establish clinical practice facilities nationwide starting in the fourth quarter. The firm plans to train health care professionals from CNS Wellness' existing Tampa office.
Wellness Center USA Inc. purchased CNS Wellness in an all-stock transaction. The Wellness Center USA paid for CNS Wellness in 7.3 million shares of Wellness Center USA stock.
CNS Wellness' former principals, Dr. William Lambos and Peter Hannouche, will serve as CNS's president/chief scientific officer and CEO, respectively, and joined Wellness Center USA's board of directors.
CNS Wellness' financial results will be consolidated with Wellness Center USA Inc., starting with the fiscal quarter ended Sept. 30.
“CNS breakthrough technology improves learning and behavioral abilities for children with ADHD and autism, without the burden of drug dependency,” Andrew Kandalepas, CEO of Wellness Center USA, says in a press release. “We also have great expectations for a positive impact on the cost of treatment for the public and healthcare system, as CNS achieves awareness through national presence.”
Depending on the severity of a disorder, CNS Wellness treatments range from six to 15 weeks, and typically cost $4,000 to $10,000. In most cases, the results are permanent.
NeoGenomics debuts first U.S. test for SF3B1 gene mutation
Fort Myers-based NeoGenomics Inc. announced it has validated and launched the first molecular cancer test for clinical use in the U.S. that detects mutations in the SF3B1 gene. Studies have indicated a possible link between mutations of SF3B1 and chronic lymphocytic leukemia and a collection of blood-related medical diseases called myelodysplastic syndromes.
The new test is offered by itself or in conjunction with a new comprehensive predictive profiling panel for patients with chronic lymphocytic leukemia. The profile panel also includes tests for a variety of other risk factor mutations, including for IgVH and ZAP-70.
By far the most common form of leukemia, chronic lymphocytic leukemia, accounts for a third of the 47,000 leukemia cases diagnosed in the U.S. each year.
“Chronic lymphocytic leukemia can have significantly different severity depending on the genomic makeup of the leukemic cells,” Dr. Maher Albitar, the company's chief medical officer and director of research and development, says in a press release. “Our goal is to provide patients and their treating physicians with the most comprehensive prognostic indicators available so that treatment options and management can be well-planned and precisely tailored for each individual patient.”
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
